Document is current

Article History

Accepted: 8 May 2025

First Online: 31 May 2025

Declarations

:

: This work was supported by Edwards Lifesciences.

: The data underlying this article will be shared on reasonable request to the corresponding author.

: The Microsoft Excel model used in this study is not publicly available. Nonetheless, a detailed explanation of the model is provided in the main text and supplementary information.

: M.A., S.C., D.P., and L.M. received funding from Edwards Lifesciences for collaboration in this study. J.D., A.W., P.G., and M.M. are employed at Edwards Lifesciences. S.L.H. and C.C. are consultants of Axentiva Solutions, which received consultancy fees from Edwards Lifesciences, Spain, and during the conduct of this study, from other pharmaceutical companies in unrelated projects.

: M.A., S.C., D.P., and L.M. participated in the review and validation of the model methodology, parameters and assumptions, resource use, and unit costs, as well as in the manuscript review process. J.D., P.G., M.M., and A.W. participated in the project conceptualization, administration, supervision, and manuscript drafting. C.C. participated in the conceptualization of the study, methodology, analysis, and manuscript drafting. S.L.H. participated in the analysis and manuscript drafting. All authors reviewed the manuscript. All authors agree to be accountable for all aspects of the work and give their consent to publish this study.

: Not applicable.

: Not applicable.

: Not applicable.